Chairs

  • Emily Breidbart
  • Sowmya Krishnan

BOD Liaison

Laurie Cohen

Charged with keeping the Society informed on topics about both new and existing drugs and devices. To review problems related to the therapeutics of Pediatric Endocrine disorders and report to the Board of Directors and the greater membership of PES.

New Meds and Tech: FDA Alert for Medical Providers Regarding Necrolytic Migratory Erythema (NME) with Chronic Glucagon Use
January 1, 2020

Overview

The FDA recently approved a Safety Labeling Change (SLC) addressing the risk of necrolytic migratory erythema (NME) with continuous intravenous glucagon use. This change has been made because of case reports of NME, including three pediatric and three adult cases. All of the pediatric cases were also reported to the FDA Adverse Event Reporting System (FAERS). The first citation below contains two of the pediatric cases. One adult case (Mullans, et al.) was only available from the literature; the other two adult cases were also reported to FAERS. The FDA does not know the incidence of NME nor the incidence of off-label use of glucagon.

For the full wording of the label change, please log in.

Not a member?

Join PES